Cytosorbents’ (CTSO) “Buy” Rating Reaffirmed at D. Boral Capital

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a $10.00 price objective on the medical research company’s stock.

Several other equities analysts have also recently issued reports on the stock. HC Wainwright reiterated a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research report on Monday, November 11th. StockNews.com assumed coverage on shares of Cytosorbents in a research report on Monday. They set a “hold” rating on the stock. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Price Performance

Shares of NASDAQ CTSO opened at $0.94 on Monday. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $1.59. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The company’s 50-day moving average is $0.92 and its 200 day moving average is $1.03. The stock has a market capitalization of $51.27 million, a P/E ratio of -2.60 and a beta of 0.58.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds and other institutional investors have recently bought and sold shares of CTSO. Atomi Financial Group Inc. purchased a new stake in Cytosorbents in the third quarter worth about $51,000. Geode Capital Management LLC grew its holdings in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares during the last quarter. Finally, Sargent Investment Group LLC lifted its position in Cytosorbents by 4.9% during the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 67,181 shares during the period. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.